Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats

Bone

Volumn 67, Issue , 2014, Pages 305-313

  Stolina, Marina ^a   Dwyer, Denise ^a   Niu, Qing Tian ^a   Villasenor, Kelly S ^a   Kurimoto, Pam ^a   Grisanti, Mario ^a   Han, Chun Ya ^a   Liu, Min ^a   Li, Xiaodong ^a   Ominsky, Michael S ^a   Ke, Hua Z ^a   Kostenuik, Paul J ^a  

^a AMGEN INC   (United States)

Author keywords

Bone formation; Bone resorption; Bone turnover markers; DKK 1; Osteoporosis; Sclerostin

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CALCEIN; COLLAGEN; DICKKOPF 1 PROTEIN; MESSENGER RNA; NEUTRALIZING ANTIBODY; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROCOLLAGEN 1 N TELOPEPTIDE; SCLEROSTIN ANTIBODY; TARTRATE RESISTANT ACID PHOSPHATASE 5B; UNCLASSIFIED DRUG; ANTIBODY; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; BLOOD ANALYSIS; BONE MARROW CELL; BONE MASS; BONE TURNOVER; CONTROLLED STUDY; CORTICAL BONE; EX VIVO STUDY; FEMALE; FEMUR; GENE EXPRESSION; MORPHOMETRICS; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOCYTE; OSTEOLYSIS; OVARIECTOMY; PERIOSTEUM; PROTEIN EXPRESSION; RAT; RNA ANALYSIS; SPRAGUE DAWLEY RAT; TIBIA; TRABECULAR BONE; TREATMENT DURATION; VERTEBRA; ANIMAL; BONE DENSITY; BONE DEVELOPMENT; DRUG EFFECTS; GENETIC MARKER; IMMUNOLOGY;

ANIMALS; ANTIBODIES; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; FEMALE; GENETIC MARKERS; OSTEOCLASTS; OSTEOGENESIS; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84905673488     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.07.031     Document Type: Article

References (31)

1. Li X., Ominsky M.S., Niu Q.T., Sun N., Daugherty B., D'Agostin D., et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008, 23:860-869.
2. Balemans W., Ebeling M., Patel N., Van Hul E., Olson P., Dioszegi M., et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001, 10:537-543.
3. Brunkow M.E., Gardner J.C., Van Ness J., Paeper B.W., Kovacevich B.R., Proll S., et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001, 68:577-589.
4. Ke H.Z., Richards W.G., Li X., Ominsky M.S. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 2012, 33:747-783.
5. Li X., Ominsky M.S., Warmington K.S., Morony S., Gong J., Cao J., et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009, 24:578-588.
6. Ominsky M.S., Li C., Li X., Tan H.L., Lee E., Barrero M., et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 2011, 26:1012-1021.
7. Padhi D., Jang G., Stouch B., Fang L., Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011, 26:19-26.
8. McColm J., Hu L., Womack T., Tang C.C., Chiang A.Y. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res 2014, 29:935-943.
9. Li X., Warmington K.S., Niu Q.T., Asuncion F.J., Barrero M., Grisanti M., et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 2010, 25:2647-2656.
10. Tian X., Jee W.S., Li X., Paszty C., Ke H.Z. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone 2011, 48:197-201.
11. Eddleston A., Marenzana M., Moore A.R., Stephens P., Muzylak M., Marshall D., et al. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res 2009, 24:1662-1671.
12. Ominsky M.S., Vlasseros F., Jolette J., Smith S.Y., Stouch B., Doellgast G., et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010, 25:948-959.
13. McClung M.R., Grauer A., Boonen S., Bolognese M.A., Brown J.P., Diez-Perez A., et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014, 370:412-420.
14. Li X., Ominsky M.S., Warmington K.S., Niu Q.T., Asuncion F.J., Barrero M., et al. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology 2011, 152:3312-3322.
15. Ominsky M., Samadfam R., Jolette J., Smith S.Y., Ke H.Z., Boyce R.W. Long-term sclerostin antibody treatment in cynomolgus monkeys: sustained improvements in vertebral microarchitecture and bone strength following a temporal increase in cancellous bone formation. J Bone Miner Res 2012, 27:S124.
16. Ellies D.L., Viviano B., McCarthy J., Rey J.P., Itasaki N., Saunders S., et al. Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res 2006, 21:1738-1749.
17. Semenov M.V., He X. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J Biol Chem 2006, 281:38276-38284.
18. Thorson S., Prasad T., Sheu Y., Danielson M.E., Arasu A., Cummings S.R., et al. Sclerostin and bone strength in women in their 10th decade of life. J Bone Miner Res 2013, 28:2008-2016.
19. Frost H.M. Bone "mass" and the "mechanostat": a proposal. Anat Rec 1987, 219:1-9.
20. Robling A.G., Niziolek P.J., Baldridge L.A., Condon K.W., Allen M.R., Alam I., et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 2008, 283:5866-5875.
21. National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals Guide for the Care and Use of Laboratory Animals 2011, National Academies Press (US), Washington (DC), [Available at: http://grants.nih.gov/grants/olaw/Guide-for-the-care-and-use-of-laboratory-animals.pdf.]. 8th ed.
22. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 2:595-610.
23. Dempster D.W., Compston J.E., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2013, 28:2-17.
24. Shahnazari M., Dwyer D., Chu V., Asuncion F., Stolina M., Ominsky M., et al. Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice. Bone 2012, 50:628-637.
25. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
26. Gatti D., Viapiana O., Adami S., Idolazzi L., Fracassi E., Rossini M. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone 2012, 50:739-742.
27. Gatti D., Viapiana O., Fracassi E., Idolazzi L., Dartizio C., Povino M.R., et al. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. J Bone Miner Res 2012, 27:2259-2263.
28. Gatti D., Viapiana O., Idolazzi L., Fracassi E., Rossini M., Adami S. The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab 2011, 96:1555-1559.
29. Butler J.S., Murray D.W., Hurson C.J., O'Brien J., Doran P.P., O'Byrne J.M. The role of Dkk1 in bone mass regulation: correlating serum Dkk1 expression with bone mineral density. J Orthop Res 2011, 29:414-418.
30. Xiong J., Onal M., Jilka R.L., Weinstein R.S., Manolagas S.C., O'Brien C.A. Matrix-embedded cells control osteoclast formation. Nat Med 2011, 17:1235-1241.
31. Li X., Warmington K.S., Niu Q.-T., Asuncion F.J., Dwyer D., Grisanti M., Han C.-Y., Kostenuik P.J., Stolina M., Ominsky M.S., Ke H.Z. Increased bone mass and bone strength by sclerostin antibody is maintained by a RANKL inhibitor in ovariectomized rats with established osteopenia. J. Bone Miner. Res. 2012, 27:S20-S21.